ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO839

Clinical Outcomes and Health Care Resource Utilization Associated with Post-Transplant Neutropenia Among Kidney Transplant Recipients: A Real-World Evidence Study

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical


  • Li, Qinghua, Merck & Co Inc, Rahway, New Jersey, United States
  • Turzhitsky, Vladimir, Merck & Co Inc, Rahway, New Jersey, United States
  • Moise, Pamela, Merck & Co Inc, Rahway, New Jersey, United States
  • Brzozowski, Kaylen, TriNetX LLC, Cambridge, Massachusetts, United States
  • Kolobova, Irina, Merck & Co Inc, Rahway, New Jersey, United States

Cytomegalovirus (CMV) remains one of the leading opportunistic infections after kidney transplantation (KT). Valganciclovir is the preferred drug for CMV prophylaxis, but neutropenia limits its use. The objective of this study was to examine the differences in clinical outcomes and HCRU among KT recipients (KTRs) with and without PTN.


This retrospective cohort study utilized the TriNetX Dataworks – USA Network, a federated network of de-identified electronic health record data for over 86 million patients in the US. Adult KTRs who received their first KT between 1/1/2012 and 9/30/2020 and valganciclovir/ganciclovir within 30 days post-KT were included. PTN was defined by laboratory ANC of <1000 cells/µl. We ran Chi-square tests for categorical variables and t-tests for continuous variables.


Among 8,791 KTRs included in this study, 2,149 (24.4%) developed PTN. Table 1 presents the comparison on clinical and HCRU outcomes. A higher proportion of KTRs with PTN had CMV infections/disease (12.1% vs. 4.4%), other opportunistic infections (e.g., bacterial septicemia (13.1 vs 8.4%)), graft rejection (30.5% vs. 25.8%), graft loss (7.6% vs. 5.2%), new-onset of diabetes mellitus (32.8% vs. 21.5%), and received dialysis (30.5% vs 25.8%) within 1 year post-KT. KTRs with PTN (vs. without) were more like to have hospitalizations (63.1% vs. 55.9%), ER visits (37.5% vs. 32.0%), outpatient visits (mean number of visits: 39.3 vs. 33.0), blood transfusions (23.5% vs. 20.1%), and G-CSF use (54.2% vs. 5.2%).


KTRs with PTN tended to experience more opportunistic infections, worse graft outcomes and higher HCRU. The findings suggest the need for treatment options to reduce the risk of PTN among KTRs to improve clinical outcomes and reduce HRCU post-KT.


  • Commercial Support – Merck & Co. Inc